Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But ...

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.

Zepbound sales totaled $4.9 billion worldwide last year, while Wegovy earned nearly $8.8 billion. Both drugs were recently removed from the U.S. Food and Drug Administration's shortage list.

Wegovy brought in nearly $8.8 billion ... Tirzepatide and semaglutide were removed recently from a list of drug shortages by the U.S. Food and Drug Administration. Both manufacturers recently ...